Lucid Diagnostics (NASDAQ:LUCD) Rating Lowered to Sell at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

LUCD has been the topic of a number of other reports. Ascendiant Capital Markets increased their target price on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Lucid Diagnostics has a consensus rating of “Moderate Buy” and a consensus target price of $3.94.

Lucid Diagnostics Stock Down 1.4%

LUCD stock opened at $1.37 on Friday. The business has a 50 day moving average of $1.28 and a 200 day moving average of $1.18. The firm has a market cap of $188.62 million, a PE ratio of -1.32 and a beta of 1.18. Lucid Diagnostics has a twelve month low of $0.95 and a twelve month high of $1.80.

Institutional Investors Weigh In On Lucid Diagnostics

Institutional investors have recently modified their holdings of the business. Centiva Capital LP purchased a new position in Lucid Diagnostics in the 3rd quarter worth about $25,000. Sprott Inc. purchased a new stake in shares of Lucid Diagnostics during the 3rd quarter valued at about $25,000. SG Americas Securities LLC purchased a new stake in shares of Lucid Diagnostics during the 3rd quarter valued at about $26,000. Quadrature Capital Ltd bought a new stake in shares of Lucid Diagnostics in the second quarter worth approximately $29,000. Finally, Abel Hall LLC bought a new stake in shares of Lucid Diagnostics in the fourth quarter worth approximately $33,000. 74.01% of the stock is owned by hedge funds and other institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.